Results 171 to 180 of about 153,102 (279)

Targeting BCL-xL in Myeloid Malignancies: From Inhibitors to PROTAC. [PDF]

J Cell Mol Med
Cilloni D, Ferrando A, Frassoni F.
europepmc   +1 more source

Integrating antibody–drug conjugates into solid tumor oncology: Current standards and future directions

Cancer, Volume 132, Issue S1, 1 June 2026.
Abstract Antibody–drug conjugates (ADCs) represent a major advance in precision oncology, combining the selectivity of monoclonal antibodies with the cytotoxic potency of chemotherapy. By enabling targeted intracellular delivery of highly potent payloads, ADCs aim to maximize antitumor activity while minimizing systemic toxicity. This review summarizes
André Mansinho, Joana Albuquerque, Andreia Lopes, Emiliano Calvo   +3 more
wiley   +1 more source

From Platelet Toxicity to Precision Targeting: Evolving Strategies to Overcome Thrombocytopenia in BCL-2/BCL-XL Inhibition. [PDF]

Health Sci Rep
Mohiuddin M.
europepmc   +1 more source

Lysine lactylation‐mediated post‐translational modification: Molecular mechanisms and therapeutic target exploration in tumour drug resistance

Clinical and Translational Medicine, Volume 16, Issue 6, June 2026.
Lysine lactylation (Kla) serves as a metabolic–epigenetic switch governed by writer–eraser–reader regulatory systems, directly connecting the Warburg effect to diverse forms of tumour drug resistance. Intratumoural lactylation critically contributes to treatment failure in chemotherapy, targeted therapy and immunotherapy.
Juan Li, Yan Shang, Haojie Wu, Shenglong Yang, Maiqun Zuo, Hailong Zhao   +5 more
wiley   +1 more source

miR‐941 in extracellular vesicles confers anlotinib resistance via Keap1/Nrf2 axis and represents a therapeutic target in non‐small cell lung cancer

Clinical and Translational Medicine, Volume 16, Issue 6, June 2026.
EV‐derived miR‐941 as a key driver of anlotinib resistance via the Keap1/Nrf2 pathway represent a promising non‐invasive predictive biomarker and a potential therapeutic target for overcoming resistance in NSCLC. Abstract Background Anlotinib is a multitargeted tyrosine kinase inhibitor for the treatment of advanced non‐small cell lung cancer (NSCLC ...
Aimi Huang, Xiaoqi Li, Erpeng Wu, Menglan Hao, Weimin Wang, Jinjing Xia   +5 more
wiley   +1 more source

BCL-xL as a therapeutic target in cetuximab-refractory colorectal cancer. [PDF]

Cell Death Dis
Asmanidou S, Thiel J, Ekstrom TL, Schueler J, Oswald E, Metzger P, Blaumeiser AC, Boerries M, Wiebl LM, Schiffler R, Tamas R, Essmann F, Dong M, Johnsen SA, Kontermann RE, Olayioye MA.   +15 more
europepmc   +1 more source

Role of Autophagy in BCL-2/BCL-XL Mediated G0 Arrest

, 2007
Although many studies have investigated the pro- and anti-apoptotic functions of the Bcl-2 family of proteins, it has been found that the anti-apoptotic Bcl-2 and Bcl-xL molecules also have a role in the cell cycle.
Valentin-Santiago, Mayda
core  

Food and Medicine Homologous Plants in Osteoporosis: A Scoping Review of Preclinical Evidence

Food Science &Nutrition, Volume 14, Issue 6, June 2026.
Food and medicine homologous (FMH) plants and their bioactive compounds exhibit potential osteoprotective effects through multiple complementary mechanisms, including estrogen‐like signaling, attenuation of oxidative stress, modulation of the gut microbiota–bone axis, and regulation of autophagy.
Long Zhao, Xiao‐li Dong, Rui‐ting Li, Qu‐huan Ma, Xiao‐feng Shi   +4 more
wiley   +1 more source

SADS-CoV NS3 induces apoptosis by blocking the formation of Bcl-xL-BAK complex. [PDF]

J Virol
Mou C, Liu M, Xiang Y, Lin C, Zhang S, Shi K, Feng S, Ma J, Chen Z.   +8 more
europepmc   +1 more source

A Review of Extraction, Structural Properties, Biological Activities of Dendrobium chrysotoxum Polysaccharides

Food Science &Nutrition, Volume 14, Issue 6, June 2026.
Overview of extraction, biological activities, and application prospects of DCP. (a) Collection, weighing, shearing, and grinding of D. chrysotoxum stems. (b) Aqueous extraction, ultracentrifugation, drying, and filtration to obtain purified DCP. (c) Mechanistic studies and preclinical or retrospective clinical investigations of DCP bioactivities.
Xingshuai Zhang, Zhaoyuan Xu, Jialin Chen, Weitong Zhang, Lihang Xie   +4 more
wiley   +1 more source